PeterHughO'DonnellMD

Oncology • Chicago, IL

Genitourinary Oncology, Hematologic Oncology

Assistant Professor of Medicine, University of Chicago, Pritzker School of Medicine

Join to view full profile

Dr. O'Donnell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. O'Donnell's full profile

Already have an account?

Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637
Phone+1 773-702-7564

Fax+1 773-702-3163
Is this information wrong?

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
University of ChicagoResidency, Internal Medicine, 2004 - 2006
University of North Carolina HospitalsResidency, Internal Medicine, 2003 - 2004
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

IL State Medical License 2004 - 2023
NC State Medical License 2003 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Investigation of Genetic Determinants of Capecitabine Toxicity Start of enrollment: 2009 Nov 01
Active, not recruiting
Investigation of Cisplatin-Related Kidney Toxicity Start of enrollment: 2009 Sep 22
Completed
Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer Start of enrollment: 2009 Oct 01
Completed
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing Start of enrollment: 2011 Jan 14
Recruiting
Afatinib in Advanced Refractory Urothelial Cancer Start of enrollment: 2013 Oct 30
Recruiting
Phase 2
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Start of enrollment: 2017 May 16
Active, not recruiting
Phase 2
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care Start of enrollment: 2022 Feb 07
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

3 citations
The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System
Sean P. David, Lavisha Singh, Jaclyn Pruitt, Andrew Hensing, Peter J. Hulick, David O. Meltzer, Peter H. O'Donnell, Henry M. Dunnenberger> ;Journal of Personalized Medicine. 2021 Nov 23
6 citations
Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform.
Nga Yeung Tang, Xun Pei, David L. George, Larry House, Keith Danahey, Elizabeth Lipschultz, Mark J. Ratain, Peter H. O'Donnell, Kiang-Teck J. Yeo, Xander M R van Wijk> ;The Journal of Applied Laboratory Medicine. 2021 Nov 1
4 citations
Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics.
Loren Saulsberry, Keith Danahey, Brittany A. Borden, Elizabeth Lipschultz, Maimouna Traore, Mark J. Ratain, David O. Meltzer, Peter H. O'Donnell> ;NPJ Genomic Medicine. 2021 Nov 1
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.
Tien M. Truong, Jeffrey L. Apfelbaum, Emily Schierer, Keith Danahey, Brittany A. Borden, Theodore Karrison, Sajid Shahul, Rebecca M. Gerlach, Randall W. Knoebel, David...> ;Pharmacogenetics and Genomics. 2021 Sep 23
9 citations
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid Treated Oncology Patients.
Natalie Reizine, Keith Danahey, Emily Schierer, Ping Liu, Merisa Middlestadt, Jenna Ludwig, Tien M. Truong, Xander M R van Wijk, Kiang-Teck J. Yeo, Monica Malec, Mark ...> ;The Oncologist. 2021 Aug 23
3 citations
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application
Brittany A. Borden, Ellie H. Jhun, Keith Danahey, Emily Schierer, Jeffrey L. Apfelbaum, Randall W. Knoebel, Sajid Shahul, Tien M. Truong, Mark J. Ratain, Peter H. O'Do...> ;The Pharmacogenomics Journal. 2021 Aug 10
4 citations
Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system.
Elizabeth Lipschultz, Keith Danahey, Tien M. Truong, Emily Schierer, Samuel L. Volchenboum, Mark J. Ratain, Peter H. O'Donnell> ;JAMIA Open. 2021 Jul 1
16 citations
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Corey C. Foster, Gini F. Fleming, Theodore Karrison, Chih-Yi Liao, Ami V. Desai, John W. Moroney, Mark J. Ratain, Rita Nanda, Blase N. Polite, Olwen Hahn, Peter H. O'D...> ;Clinical Cancer Research. 2021 Jun 24
4 citations
EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma
Antic Tatjana, Melissa Y. Tjota, Peter H. O'Donnell, Scott E. Eggener, Piyush K. Agarwal, Rishikesh Haridas, Jeremy P. Segal, Peng Wang> ;Virchows Archiv. 2021 Jun 14
102 citations
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y. Yu, Daniel P. Petrylak, Peter H. O'Donnell, Jae-Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. ...> ;The Lancet. Oncology. 2021 Jun 1
178 citations
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj ...> ;The Lancet. Oncology. 2021 Apr 1
1 citations
Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis
Pankti Reid, Keith Danahey, Marco Lopez Velazquez, Mark J. Ratain, Peter H. O'Donnell> ;Clinical and Experimental Rheumatology. 2021 Jan 15
11 citations
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
Natalie Reizine, Everett E. Vokes, Ping Liu, Tien M. Truong, Rita Nanda, Gini F. Fleming, Daniel V.T. Catenacci, Alexander T. Pearson, Sandeep Parsad, Keith Danahey, X...> ;Therapeutic Advances in Medical Oncology. 2020 Dec 17
6 citations
Patient insights on features of an effective pharmacogenomics patient portal.
Tien M. Truong, Elizabeth Lipschultz, Emily Schierer, Keith Danahey, Mark J. Ratain, Peter H. O'Donnell> ;Pharmacogenetics and Genomics. 2020 Oct 3
23 citations
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R. Harrison, Peter H. O'Donnell, Ajjai Alva, Noah M. Hahn, Leonard Joseph Appleman, Jeremy Cetnar, John M. Burke, Mark D. Fleming, Matthew I. Milow...> ;Cancer. 2020 Oct 15
1 citations
Incorporating preemptive pharmacogenomic testing into the clinical setting.
Peter H. O'Donnell> ;Clinical Advances in Hematology & Oncology. 2020 Sep 1
10 citations
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications.
Carlton Christian, Brittany A. Borden, Keith Danahey, Kiang-Teck J. Yeo, Xander M R van Wijk, Mark J. Ratain, Peter H. O'Donnell> ;Clinical Pharmacology and Therapeutics. 2020 Aug 1
137 citations
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelia...
Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Sava...> ;Journal of Clinical Oncology. 2020 Jun 17
26 citations
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Petros Grivas, Elizabeth R. Plimack, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Joaquim Bellmunt, Thomas Powles, Noah M. Hahn, Ronald de Wit, Dean F. B...> ;European Urology Oncology. 2020 Jun 1
6 citations
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015
Peter H. O'Donnell, Vassily V. Trubetskoy, Ashley Nurhussein-Patterson, Julianne P. Hall, Aritro Nath, Dezheng Huo, Gini F. Fleming, James N. Ingle, Vandana G. Abramso...> ;Breast Cancer Research and Treatment. 2020 May 6
13 citations
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation.
Wenndy Hernandez, Keith Danahey, Xun Pei, Kiang-Teck J. Yeo, Edward Ki Yun Leung, Samuel L. Volchenboum, Mark J. Ratain, David O. Meltzer, Barbara E. Stranger, Minoli ...> ;The Pharmacogenomics Journal. 2020 Feb 1
10 citations
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escal...
Peter H. O'Donnell, Hendrick Tobias Arkenau, Srikala S. Sridhar, Michael Ong, Alexandra Drakaki, Alexander I. Spira, Jingsong Zhang, Michael S. Gordon, Arnold Degboe, ...> ;Cancer. 2020 Jan 15
8 citations
Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal
Tien M. Truong, Elizabeth Lipschultz, Keith Danahey, Emily Schierer, Mark J. Ratain, Peter H. O'Donnell> ;Clinical and Translational Science. 2020 Jan 1
15 citations
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care.
Tien M. Truong, Jeffrey L. Apfelbaum, Sajid Shahul, Keith Danahey, Randall W. Knoebel, David Liebovitz, Theodore Karrison, Xander M R van Wijk, Kiang-Teck J. Yeo, Davi...> ;Clinical Pharmacology and Therapeutics. 2019 Dec 1
340 citations
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Jonathan E. Rosenberg, Peter H. O'Donnell, Arjun Vasant Balar, Bradley Alexander McGregor, Elisabeth I. Heath, Evan Y. Yu, Matthew D. Galsky, Noah M. Hahn, Elaina M. G...> ;Journal of Clinical Oncology. 2019 Jul 29
Join now to see all

Lectures

KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)â€” Updated response and survival results.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
UTSW Finds Potential Key to Predict Immunotherapy ToxicityAugust 15th, 2023